Enzastaurin for Patients With Metastatic Colorectal Cancer

NCT00192114 ↗

Phase 2 Completed 28 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer

Timeline

Start: 2005-08
Primary completion: 2008-03
Completion: 2008-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	enzastaurin	Small molecule	500 mg	Oral

Enzastaurin for Patients With Metastatic Colorectal Cancer

Summary

Timeline

Drugs

Indications